Stockreport

Sesen Bio announces an exclusive license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum™ in Greater China

Sesen Bio, Inc.  (SESN) 
Last sesen bio, inc. earnings: 11/12 07:00 am Check Earnings Report
PDF Sesen to receive $12 million upfront and $23 million in potential regulatory and tech transfer milestone paymentsSesen eligible to receive royalties on net sales in Chin [Read more]